Clinical trial
A Single-site, Placebo-controlled, Double-blind Trial to Investigate the Safety, Tolerability, Systemic Exposure and the Scar-improvement Efficacy of Intradermal Applications of Three Doses of Juvidex (5.64mg/100μl, 2.82mg/100μl and 11.28mg/100μl) Given Once Only or Three Times Within and Between Male and Female Subjects Aged 18-45.
NCT00984516 is registered in ClinicalTrials.gov with Renovo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-site, Placebo-controlled, Double-blind Trial to Investigate the Safety, Tolerability, Systemic Exposure and the Scar-improvement Efficacy of Intradermal Applications of Three Doses of Juvidex (5.64mg/100μl, 2.82mg/100μl and 11.28mg/100μl) Given Once Only or Three Times Within and Between Male and Female Subjects Aged 18-45.
- Lead sponsor
- Renovo
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2004
- Completion date
- January 31, 2006
- Enrollment
- 102 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cicatrix, wound-healing